Literature DB >> 30179566

Tumor Mutation Burden: Is It Ready for the Clinic?

Yasushi Goto1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30179566     DOI： 10.1200/JCO.2018.79.3398

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Tumor mutation burden: from comprehensive mutational screening to the clinic.

Authors:  Francesca Galuppini; Carlo Alberto Dal Pozzo; Matteo Fassan; Raffaele Baffa; Jutta Deckert; Fotios Loupakis
Journal:  Cancer Cell Int       Date:  2019-08-07       Impact factor: 5.722

Review 2.  Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?

Authors:  Vasiliki Siozopoulou; Andreas Domen; Karen Zwaenepoel; Annelies Van Beeck; Evelien Smits; Patrick Pauwels; Elly Marcq
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

3.  Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.

Authors:  Michael Wessolly; Susann Stephan-Falkenau; Anna Streubel; Marcel Wiesweg; Sabrina Borchert; Elena Mairinger; Jens Kollmeier; Henning Reis; Torsten Bauer; Kurt Werner Schmid; Thomas Mairinger; Martin Schuler; Fabian D Mairinger
Journal:  BMC Cancer       Date:  2022-01-07       Impact factor: 4.430

4.  ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis.

Authors:  Yanna Zhang; Ting Du; Xiancheng Chen
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

5.  Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.

Authors:  Wenjing Zhang; Yunfeng Tang; Yuxian Guo; Yujia Kong; Fuyan Shi; Chao Sheng; Suzhen Wang; Qinghua Wang
Journal:  NPJ Precis Oncol       Date:  2022-06-23

Review 6.  Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.

Authors:  Sonam Puri; Michael Shafique
Journal:  Drugs Context       Date:  2020-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.